Wanbang Biopharma's Oral Diabetes Drug Passes Tox Study

China Wanbang Biopharma successfully completed the toxicology study of an oral SGLT2 Inhibitor treatment for type 2 diabetes. One year ago, Wanbang in-licensed China rights to the drug from Canada's Sirona Biochem, which is now due a milestone payment as part of the $9.5 million deal between the two companies. According to Sirona, the molecule was well tolerated, even at significantly higher doses than a reference SGLT2 inhibitor. Wanbang, a division of Fosun Pharma, focuses on diabetes and cardiovascular drugs. More details.... Stock Symbols: (TSX: SBM) (SHA: 600196; HK: 02196) Share this with colleagues: // //